This is a StreetInsider.com Premium Only Page

Dyne Therapeutics Inc. (DYN) – StreetInsider.com Reports

Mar 25, 2024 07:30 AM Dyne Therapeutics (DYN) Announces CEO Transition

Mar 8, 2024 04:21 AM Dyne Therapeutics (DYN) PT Raised to $31 at Chardan Capital Markets

Mar 6, 2024 07:55 AM Dyne Therapeutics (DYN) PT Raised to $29 at Piper Sandler

Mar 5, 2024 04:48 PM Dyne Therapeutics (DYN) PT Raised to $41 at Stifel

Mar 5, 2024 03:09 PM Dyne Therapeutics (DYN) PT Raised to $47 at Oppenheimer

Mar 5, 2024 08:25 AM Dyne Therapeutics (DYN) Files Mixed Shelf

Feb 20, 2024 06:03 AM H.C. Wainwright Starts Dyne Therapeutics (DYN) at Buy

Jan 26, 2024 02:54 PM Dyne Therapeutics Inc. (DYN) Resumes Trading Following Halted, Now Up 36%

Jan 26, 2024 02:38 PM Avidity Biosciences (RNA) Spikes 15% Following Report Dyne Therapeutics Inc. (DYN) Received Takeover Interest

Jan 26, 2024 02:31 PM Dyne Therapeutics Inc. (DYN) Said To Weigh Options Amid Takeover Interest - Bloomberg

Jan 8, 2024 07:17 AM Dyne Therapeutics (DYN) PT Lowered to $27 at Piper Sandler

Jan 5, 2024 05:44 AM Dyne Therapeutics Inc. (DYN) Prices 17.15M Share Offering at $17.50/sh

Jan 4, 2024 05:17 PM Dyne Therapeutics (DYN) Suspends ATM Offering

Jan 3, 2024 04:45 PM After-hours movers: MongoDB and Cal-Maine decline, Arena Group surges

Jan 3, 2024 04:26 PM Dyne Therapeutics Inc. (DYN) Announces $175M Proposed Public Offering of Common Stock

Jan 3, 2024 03:59 PM Dyne Therapeutics (DYN) PT Raised to $25 at JPMorgan

Jan 3, 2024 08:31 AM Dyne Therapeutics (DYN) PT Raised to $44 at Oppenheimer; 'Expectations Exceeded Across the Board'

Jan 3, 2024 07:08 AM Dyne Therapeutics (DYN) Climbs 100% Following Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial Data

Jan 3, 2024 06:30 AM Dyne Therapeutics (DYN) Reports Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial

Oct 30, 2023 07:52 AM Dynegy (DYN) Misses Q3 EPS by 16c

Sep 20, 2023 04:08 PM Dyne Therapeutics (DYN) Granted FDA Orphan Drug Designation for DYNE-101

Aug 9, 2023 07:14 AM Dyne Therapeutics (DYN) PT Raised to $22 at JPMorgan

May 25, 2023 07:30 AM Dyne Therapeutics (DYN) Granted EU Orphan Drug Designation for DYNE-101

May 25, 2023 07:11 AM Dyne Therapeutics (DYN) PT Lowered to $20 at JPMorgan

Mar 23, 2023 07:31 AM Dyne Therapeutics Inc. (DYN) Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Mar 20, 2023 07:31 AM Dyne Therapeutics (DYN) Announces Presentations on its DM1 and DMD Programs

Mar 3, 2023 06:53 AM Dyne Therapeutics (DYN) PT Raised to $20 at Chardan Capital Markets

Feb 27, 2023 03:25 AM Raymond James Upgrades Dyne Therapeutics (DYN) to Strong Buy

Feb 14, 2023 04:03 PM Oppenheimer Starts Dyne Therapeutics (DYN) at Outperform, 'A FORCEful Approach, Overcoming Oligonucleotide Delivery Limitations in Muscle'

Jan 26, 2023 06:14 AM Guggenheim Starts Dyne Therapeutics (DYN) at Buy

Nov 29, 2022 07:05 AM Dyne Therapeutics (DYN) PT Lowered to $18 at JPMorgan

Nov 3, 2022 02:02 PM Dyne Therapeutics (DYN) PT Raised to $16 at Raymond James

Oct 31, 2022 07:30 AM Dyne Therapeutics (DYN) Receives FDA Fast Track Designation for DYNE-251

Oct 11, 2022 04:11 PM Dyne Therapeutics (DYN) Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53

Sep 6, 2022 12:19 PM Dyne Therapeutics (DYN) PT Raised to $23 at Piper Sandler

Sep 6, 2022 07:02 AM Dyne Therapeutics Inc. (DYN) Initiates Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 in DM1

Aug 29, 2022 07:31 AM Dyne Therapeutics Inc. (DYN) Appoints Francesco Bibbiani as SVP and Head of Development

Aug 10, 2022 07:33 AM Dyne Therapeutics Inc. (DYN) Announces Publication of Preclinical Data

Aug 10, 2022 07:32 AM Dyne Therapeutics (DYN) Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

Jul 20, 2022 06:17 AM UPDATE: Chardan Capital Markets Starts Dyne Therapeutics (DYN) at Buy

Jul 12, 2022 08:17 AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)

Jul 12, 2022 07:32 AM Dyne Therapeutics Inc. (DYN) Announces FDA Clearance of Clinical Trial Application for DYNE-101

Jul 11, 2022 04:25 PM UPDATE: Raymond James Starts Dyne Therapeutics (DYN) at Outperform

Jul 5, 2022 07:30 AM Dyne Therapeutics Inc. (DYN) Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

May 23, 2022 06:18 AM Dyne Therapeutics (DYN) PT Lowered to $12 at Piper Sandler

May 16, 2022 07:32 AM Dyne Therapeutics Inc. (DYN) Presents New In Vivo Data from DYNE-101

Mar 14, 2022 07:55 AM Dyne Therapeutics (DYN) PT Lowered to $23 at JPMorgan

Mar 11, 2022 03:23 PM Stifel Reiterates Reiterates Dyne Therapeutics (DYN) at Buy, DMD Trial Hold Remains Biggest Concern

Mar 3, 2022 07:33 AM Dyne Therapeutics Inc. (DYN) Appoints Carlo Incerti to its Board

Jan 18, 2022 08:01 AM Dyne Therapeutics Inc. (DYN) Announces FDA Places Clinical Hold on IND Application for DYNE-251